Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Biotechnology company developing AI-driven drug discovery solutions and platforms for pharma and biotech, focused on MoA analysis and novel drug.
Kaipharm, based in Seoul, South Korea, develops AI-driven drug discovery solutions, including comprehensive databases of compound structures, drug-disease relationships, drug-target relationships, and drug-induced transcriptome data. The company provides specialized platforms such as a drug-induced transcriptome tool for mode-of-action (MoA) analysis and KMAP, designed for analyzing transcriptome data to identify novel drug indications for pharmaceutical and biotechnology clients. As of early 2020, Kaipharm had secured a total of ₩7 billion, equivalent to approximately USD 5.8 million, in venture funding to advance its AI platforms and datasets. This funding included a ₩5 billion (approximately USD 4.2 million) Series A round completed in February 2020. The company plans to generate the KMAP_2K dataset, which will encompass 2,000 drugs, including all FDA-approved compounds, utilizing next-generation sequencing. Kaipharm was founded in 2018 by CEO Wankyu Kim.
Kaipharm has raised $4.0M across 1 funding round.
Kaipharm has raised $4.0M in total across 1 funding round.
Kaipharm has raised $4.0M in total across 1 funding round.
Kaipharm's investors include Almas Investment, E&Venture Partners, Innopolis Partners, Jung Shin, Kolon Investment, P&I Investment.
Kaipharm has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in January 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 30, 2020 | $4M Series A | — | Almas Investment, E&venture Partners, Innopolis Partners, Jung Shin, Kolon Investment, P&I Investment | Announced |